Endovascular vs Medical Management for Late Anterior Large Vessel Occlusion With Prestroke Disability
Neurol 100:e751-e763, Siegler, J.E., et al, 2023
Melbourne Mobile Stroke Unit and Reperfusion Therapy
Stroke 51:922-930, Zhao, H.,et al, 2020
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:DOI:10.1056/NEJMoa1415061, DOI:10.1056 NEJM e1503217, Saver, J.L.,et al, 2015
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
NEJM 372:DOI:10.1056 NEJMoa1503780, DOI:1056NEJM e1503217, Jovin, T.G.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015
Thrombectomy within 8 hours after Symptom Onset in Ischemic Stroke
NEJM 372:2296-2306,2347, Jovin, T.G.,et al, 2015
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Recommendations for the Management of Cerebral and Cerebellar Infarction with Swelling
Stroke 45:1222-1238, Wijdicks, E.F.M.,et al, 2014
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Herpes Simplex Virus Encephalitis:Clinical Manifestations,Diagnosis and Outcome in 106 Adult Patients
J Clin Virol 60:112-118, Sili,U.,et al, 2014
Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
Evidence for Acute Neurotoxicity After Chemotherapy
Ann Neurol 68:806-815, Petzold,A.,et al, 2010
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
Primary Central Nervous System Vasculitis: Analysis of 101 Patients
Ann Neurol 62:442-451,430, Salvarani,C.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Chasing "Chasing the Dragon" with MRI: Leukoencephalopathy in Drug Abuse
Br J Radiol 78:997-1004, Bartlett,E. &Mikulis,D.J., 2005
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001
Relapses and Progression of Disability in Multiple Sclerosis
NEJM 343:1430-1438,1486, Confavreux,C.,et al, 2000
Leukoencephalopathy and Raised Brain Lactate from Heroin Vapor Inhalation ("Chasing the Dragon")
Neurol 53:589-1048, Kriegstein,A.R., et al, 1999
Randomised Double-Blind Placebo-Controlled Study of Interferon B-1a in Relapsing/Remitting Multiple Sclerosis
Lancet 352:1498-1504,1486, PRISMS, 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
A 36-Year-Old Woman Recuperating From a Stroke
JAMA 277:1970-1976, Alexander,M., 1997
Herpes Simplex Encephalitis Treated with Acyclovir:Diagnosis and Long Term Outcome
JNNP 63:321-326, McGrath,N.,et al, 1997
New Treatments for Multiple Sclerosis
BMJ 310:345-346, McDonald,W.I., 1995
Acute Viral Encephalitis in Childhood
BMJ 310:139-140, Kennedy,C., 1995
Interferon Beta-1b in the Trtm of MS:Outcome of the Randomized Controlled Trial
IFNB Study Gr, Neurol 45:1277-12851995., , 1995
Acquired Immunodeficiency Syndrome, CSF Before & During Long-Term Oral Zidovudine Therapy
Arch Neurol 48:695-699, Tartaglione,T.A.,et al, 1991
Cerebral Edema Causing Death in Children with Maple Syrup Urine Disease
J Pediatr 119:42-45, Riviello,J.J.,et al, 1991
Hemorrhagic Shock and Encephalopathy:Clinical, Pathologic, and Biochemical Features
J Pediatr 114:194-203, Levin,M.,et al, 1989